Gelteq (GELS) Competitors $1.96 -0.06 (-2.97%) As of 01/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends GELS vs. ALTS, CNTX, KPTI, IMAB, AADI, GNLX, ALLK, BGM, ADAG, and CTORShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Janone (ALTS), Context Therapeutics (CNTX), Karyopharm Therapeutics (KPTI), I-Mab (IMAB), Aadi Bioscience (AADI), Genelux (GNLX), Allakos (ALLK), Qilian International Holding Group (BGM), Adagene (ADAG), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical preparations" industry. Gelteq vs. Janone Context Therapeutics Karyopharm Therapeutics I-Mab Aadi Bioscience Genelux Allakos Qilian International Holding Group Adagene Citius Oncology Gelteq (NASDAQ:GELS) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Do insiders & institutionals have more ownership in GELS or ALTS? 6.3% of Janone shares are held by institutional investors. 4.9% of Janone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to GELS or ALTS? In the previous week, Janone had 3 more articles in the media than Gelteq. MarketBeat recorded 4 mentions for Janone and 1 mentions for Gelteq. Gelteq's average media sentiment score of 1.88 beat Janone's score of 0.95 indicating that Gelteq is being referred to more favorably in the media. Company Overall Sentiment Gelteq Very Positive Janone Positive Does the MarketBeat Community favor GELS or ALTS? Gelteq and Janone both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformGelteqN/AN/AJanoneN/AN/A Which has better valuation & earnings, GELS or ALTS? Gelteq has higher earnings, but lower revenue than Janone. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteqN/AN/AN/AN/AN/AJanone$7.11M12.13-$7.81MN/AN/A Is GELS or ALTS more profitable? Gelteq's return on equity of 0.00% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Janone N/A -2,940.01%-39.81% SummaryJanone beats Gelteq on 4 of the 7 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.50M$6.54B$5.25B$8.80BDividend YieldN/A2.91%5.07%4.00%P/E RatioN/A10.2188.0716.96Price / SalesN/A176.181,087.13123.65Price / CashN/A57.6743.2137.77Price / BookN/A4.885.054.89Net IncomeN/A$154.38M$122.32M$228.40M7 Day Performance-19.34%-5.11%-2.83%-2.25%1 Month Performance-28.47%-3.15%-1.03%-0.41%1 Year PerformanceN/A-4.63%22.93%13.53% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.96-3.0%N/AN/A$18.50MN/A0.00N/APositive NewsALTSJanoneN/A$6.47-4.9%N/AN/A$91.03M$7.11M0.00170Short Interest ↓News CoverageCNTXContext Therapeutics2.315 of 5 stars$1.21+11.0%$6.33+423.4%-16.8%$90.75MN/A-1.337Short Interest ↑Gap UpHigh Trading VolumeKPTIKaryopharm Therapeutics4.1209 of 5 stars$0.72-6.9%$5.00+598.3%-14.9%$90.35M$148.44M-0.63380IMABI-Mab2.8528 of 5 stars$1.10+12.0%$8.00+627.3%-49.3%$89.65M$3.27M0.0034Short Interest ↑AADIAadi Bioscience1.2856 of 5 stars$3.60-3.5%$1.67-53.7%+73.8%$88.73M$25.07M-1.5840Short Interest ↑News CoveragePositive NewsGNLXGenelux1.6868 of 5 stars$2.55-4.9%$18.25+615.7%-81.6%$88.07M$8,000.00-2.6810Positive NewsALLKAllakos4.6881 of 5 stars$0.98-4.9%$1.67+70.2%-70.5%$87.49MN/A-0.48190Positive NewsGap UpBGMQilian International Holding GroupN/A$11.95-8.1%N/AN/A$86.36M$29.87M0.00298Positive NewsGap UpADAGAdagene2.4304 of 5 stars$1.95-5.3%$5.00+156.4%-43.2%$86.33M$815,746.000.00260Short Interest ↑Positive NewsCTORCitius OncologyN/A$1.18-13.2%$3.00+154.2%N/A$84.43MN/A0.00N/APositive NewsGap Up Related Companies and Tools Related Companies Janone Competitors Context Therapeutics Competitors Karyopharm Therapeutics Competitors I-Mab Competitors Aadi Bioscience Competitors Genelux Competitors Allakos Competitors Qilian International Holding Group Competitors Adagene Competitors Citius Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GELS) was last updated on 1/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GELS Stock Alerts